<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="103687"><DrugName>RVT-801</DrugName><CompanyOriginator id="1104160">Roivant Sciences Ltd</CompanyOriginator><CompaniesPrimary><Company id="1104160">Roivant Sciences Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1104160" type="Company"><TargetEntity id="5046658821" type="organizationId">Roivant Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="648" type="ciIndication"><TargetEntity id="10024579" type="MEDDRA"></TargetEntity><TargetEntity id="D016464" type="MeSH"></TargetEntity><TargetEntity id="-563478016" type="omicsDisease"></TargetEntity><TargetEntity id="977" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="584">Lipid metabolism disorder</Indication><Indication id="648">Lysosome storage disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="16836">Acid ceramidase stimulator</Action></ActionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="901">Recombinant enzyme</Technology></Technologies><LastModificationDate>2019-06-17T07:15:08.000Z</LastModificationDate><ChangeDateLast>2019-03-12T00:00:00.000Z</ChangeDateLast><AddedDate>2016-10-27T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1104160" linkType="Company"&gt;Roivant Sciences&lt;/ulink&gt; is investigating RVT-801, an enzyme replacement therapy based on recombinant human acid ceramidase (rhAC), for the potential treatment of Farber disease (acid ceramidase deficiency) [&lt;ulink linkID="1804308" linkType="Reference"&gt;1804308&lt;/ulink&gt;], [&lt;ulink linkID="2007180" linkType="Reference"&gt;2007180&lt;/ulink&gt;].   In February 2019, in vivo data were presented [&lt;ulink linkID="2118962" linkType="Reference"&gt;2118962&lt;/ulink&gt;]. In June 2018, an IND was planned to be filed [&lt;ulink linkID="2040968" linkType="Reference"&gt;2040968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, the drug was  listed as being in phase I development  [&lt;ulink linkID="1804308" linkType="Reference"&gt;1804308&lt;/ulink&gt;]. However, in February 2017, the drug was listed as being in preclinical development [&lt;ulink linkID="1900356" linkType="Reference"&gt;1900356&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;REGULATORY INFORMATIONThe US&lt;/subtitle&gt;By February 2018, an Orphan drug designation for RVT-801 had been granted in the US [&lt;ulink linkID="2007180" linkType="Reference"&gt;2007180&lt;/ulink&gt;]. In March 2019, the US FDA  granted Rare Pediatric Disease and Fast Track designations for RVT-801 for the treatment Farber disease  [&lt;ulink linkID="2132091" linkType="Reference"&gt;2132091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By February 2018, an Orphan drug designation for RVT-801 had been granted in the European Union [&lt;ulink linkID="2007180" linkType="Reference"&gt;2007180&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2018, a  first-in-human clinical study in patients with Farber disease was planned to initiate [&lt;ulink linkID="2007180" linkType="Reference"&gt;2007180&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2019, in vivo data were presented at the 15th Annual Lysosomal Disease Network WORLD Symposium in Orlando, FL. In Farber mouse model, intraperitoneal RVT-801 treatment at doses of 0.1, 1, 3 or 10 mg/kg (qw) for 6 weeks led to amelioration of joint pathology resembling clinical nodules and granulomas, including normalized bone structure. RVT-801 administration led to a dose-dependent decrease in plasma MCP-1 and ceramide levels in the liver, spleen, kidney, heart, brain and muscle; increased sphingosine in a subset of tissues; improved body weight gain; and resolved splenomegaly [&lt;ulink linkID="2118962" linkType="Reference"&gt;2118962&lt;/ulink&gt;]. At the same conference, further in vivo data were presented. In Farber disease mice, four qw intraperitoneal doses of RVT-801  (10 mg/kg/dose; maximally effective dose)  resulted in decreased  pro-inflammatory immune cells  with key reductions in neutrophils and activated monocytes compared to wild-type control levels in the lung, liver, blood, and to a lesser extent in the spleen    [&lt;ulink linkID="2118975" linkType="Reference"&gt;2118975&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2018, preclinical data were presented at 14th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. In knock-in juvenile Asah1 (P361R/P361R) mouse model of severe Faber disease, acute administration of 1 to 10 mg/kg RVT-801 showed a dose-dependent reduction in tissue ceramide accumulation and inflammatory cytokines. In Faber mice, AUC (0 to last) and Cmax for RVT-801 at maximally effective dose of 10 mg/kg were 2.23 h. microg/ml and 1.25 microg/ml, respectively. Liver showed highest concentration at an approximately 4 h post dose and was remained elevated beyond the last sampling time-point (24 h) where serum levels were found to be undetectable [&lt;ulink linkID="2009563" linkType="Reference"&gt;2009563&lt;/ulink&gt;].   &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="648">Lysosome storage disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-09T00:00:00.000Z</StatusDate><Source id="2009563" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-15T00:00:00.000Z</StatusDate><Source id="1900356" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104160">Roivant Sciences Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</StatusDate><Source id="2007180" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104160">Roivant Sciences Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="648">Lysosome storage disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</StatusDate><Source id="2007180" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-04T00:00:00.000Z</StatusDate><Source id="1804308" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="648">Lysosome storage disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-15T00:00:00.000Z</StatusDate><Source id="1900356" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="648">Lysosome storage disease</Indication><AwardedIndication>Treatment of Farber disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-21T00:00:00.000Z</MileStoneDate><Source id="2132091" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication>Treatment of Farber disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-21T00:00:00.000Z</MileStoneDate><Source id="2132091" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="648">Lysosome storage disease</Indication><AwardedIndication></AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</MileStoneDate><Source id="2007180" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="648">Lysosome storage disease</Indication><AwardedIndication></AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</MileStoneDate><Source id="2007180" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication></AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</MileStoneDate><Source id="2007180" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication></AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-21T00:00:00.000Z</MileStoneDate><Source id="2007180" type="PR"></Source></Row><Row><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication>Treatment of Farber disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-21T00:00:00.000Z</MileStoneDate><Source id="2132091" type="PR"></Source></Row><Row><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><OwnerCompany id="1104160">Roivant Sciences Ltd</OwnerCompany><Country id="US">US</Country><Indication id="648">Lysosome storage disease</Indication><AwardedIndication>Treatment of Farber disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-21T00:00:00.000Z</MileStoneDate><Source id="2132091" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-04189"><Name>Acid ceramidase</Name><SwissprotNumbers><Swissprot>O45686</Swissprot><Swissprot>Q13510</Swissprot><Swissprot>Q60HH4</Swissprot><Swissprot>Q9WV54</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2159543" linkType="reference" linkID="2159543"&gt;2159543&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1104160">Roivant Sciences Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20325">Avid Bioservices Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="245713" title="Avid Bioservices to manufacture Enzyvant's RVT-801 against Farber disease"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>